The FASEB Journal: PML as potential treatment for pancreatic cancer

September 26, 2019

A recent study in The FASEB Journal identifies a new mechanism of pancreatic tumors' resistance to chemotherapeutic treatment. The mechanism involves the loss of function of promyelocytic leukemia protein (PML), which operates like a tumor suppressor. Surprisingly, researchers found that the PML dysfunction was due not to a genetic mutation or altered gene expression, but rather to an alteration of a specific type of protein modification.

To conduct the experiment, researchers first generated protein modification profiles of resistant and non-resistant cells from a pancreatic cancer cell line. By comparing the profiles, they identified specific alterations of protein modifications associated with the resistant cells. Among the resistant cells was PML, known for its involvement in an aggressive form of leukemia. Using cultured cells, the current study revealed that an altered modification of PML known as sumoylation was also involved in pancreatic cancer cells' resistance to chemotherapeutic treatment.

Using patient-derived xenografts (i.e., human tumor samples implanted in mice), researchers observed that patients with both high expression of PML and high sumoylation of PML had better rates of survival. Conversely, the study showed that patients with either low expression of PML or low sumoylation of PML had worse rates of survival, as their tumors displayed resistance to chemotherapeutic treatment.

"These findings could improve the prognosis of pancreatic cancer patients in a relatively short period of time," said Philippe Soubeyran, PhD, a researcher at the Marseilles Cancer Research Center (CRCM), National Institute for Health and Medical Research (INSERM) in France. "In the long term, we may be able to improve pancreatic cancer treatments by restoring their efficacy over resistant tumors."

"That a post-translational modification of this protein is so determinative is an intriguing finding," said Thoru Pederson, PhD, Editor-in-Chief of The FASEB Journal. "It not only resets the therapeutic dimension but may herald similar oncoprotein events in other malignancies," he said.
-end-
The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). The world's most cited biology journal according to the Institute for Scientific Information, it has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.

FASEB is composed of 29 societies with more than 130,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB's mission is to advance health and well-being by promoting research and education in biological and biomedical sciences through collaborative advocacy and service to member societies and their members.

Federation of American Societies for Experimental Biology

Related Leukemia Articles from Brightsurf:

New therapeutic approach against leukemia
Using an RNA molecule complex, researchers can prevent retention of cancer stem cell in their tumor supporting niche

Nanoparticle for overcoming leukemia treatment resistance
One of the largest problems with cancer treatment is the development of resistance to anticancer therapies.

Key gene in leukemia discovered
Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.

Vitamin B6, leukemia's deadly addiction
Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6.

Artificial intelligence tracks down leukemia
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability.

Milestone reached in new leukemia drug
Using a chemical compound called YKL-05-099, a team of cancer researchers from CSHL and the Dana Farber Institute was able to target the Salt-Inducible Kinase 3 (SIK3) pathway and extend survival in mice with MLL leukemia.

The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.

Towards a safer treatment for leukemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the Children's Cancer Institute, Australia, have found a safer treatment for a specific type of leukemia.

Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.

An atlas of an aggressive leukemia
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.

Read More: Leukemia News and Leukemia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.